News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2023 NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear L.A. McKeown November 12, 2023
News Conference News AHA 2022 ‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge L.A. McKeown November 11, 2022
News Conference News AHA 2021 Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage Todd Neale November 19, 2021
News Conference News AHA 2019 Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS Todd Neale November 20, 2019
News Conference News AHA 2019 Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR Todd Neale November 17, 2019
News Conference News AHA 2017 Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation Michael O'Riordan November 13, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2016 AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR Shelley Wood November 09, 2016